Drug Development Pipeline
Restore CFTR Function
Cavosonstat (N91115) is a compound that modulates the function of the defective CFTR protein and decreases inflammation in the lung. Cavosonstat is the first of a new class of compounds that increase levels of an important signaling molecule in the body, called S-nitrosoglutathione or GSNO. Levels of GSNO have been shown to be decreased in people with CF. These novel compounds have been shown to increase the amount of CFTR protein that reaches the cell surface and to stabilize CFTR protein so that its function can be improved.
In a phase 2 study of cavosonstat in combination with ivacaftor, cavosonstat did not demonstrate benefit in the study's primary endpoint, change in lung function.
No further clinical development in CF is planned at this time.
The program was sponsored by Nivalis Therapeutics Inc. and was conducted within the Therapeutics Development Network.
Recent Cavosonstat (N91115) Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More